Conmed (CNMD) Tops Q4 EPS by 13c ; Offers Guidance
Tweet
Share
E-mailGet Alerts CNMD Hot Sheet
Price: $32.58 +1.46%
Revenue Growth %: -0.5%
Financial Fact:
Research and development expense: 8.35M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Revenue Growth %: -0.5%
Financial Fact:
Research and development expense: 8.35M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Conmed (NYSE: CNMD) reported Q4 EPS of $1.34, $0.13 better than the analyst estimate of $1.21. Revenue for the quarter came in at $345.9 million versus the consensus estimate of $341 million.
GUIDANCE:
Conmed sees FY2025 EPS of $4.25-$4.40, versus the consensus of $4.03. Conmed sees FY2025 revenue of $1.34-1.37 billion, versus the consensus of $1.3 billion.
For earnings history and earnings-related data on Conmed (CNMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kalshi in early talks for IPO - The Information
- Grizzly Discoveries closes private placement raising $349,044
- Iran Says Hormuz To Close, Citing Ceasefire Violation- Tasnim
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
